Double or triple antithrombotic combination therapy in patients who need anticoagulation and antiplatelet therapy in parallel

European Heart Journal - Cardiovascular Pharmacotherapy

Volumn 1, Issue 3, 2015, Pages 191-197

  Rohla, Miklos ^a   Weiss, Thomas W ^a   Wojta, Johann ^b   Niessner, Alexander ^b   Huber, Kurt ^a  

^a WILHELMINEN HOSPITAL   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Antithrombotic therapy; Atrial fibrillation; Coronary stenting

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; APIXABAN; CLOPIDOGREL; DABIGATRAN; EDOXABAN; PLACEBO; PRASUGREL; RIVAROXABAN; TICAGRELOR; WARFARIN; FIBRINOLYTIC AGENT;

ACUTE CORONARY SYNDROME; ATRIAL FIBRILLATION; BLEEDING; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; CONSENSUS DEVELOPMENT; DEVICE SAFETY; DRUG DOSE COMPARISON; DUAL ANTIPLATELET THERAPY; EMBOLISM; EUROPE; HEART INFARCTION; HUMAN; MEDICAL SOCIETY; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; STENT THROMBOSIS; TREATMENT DURATION; COMBINATION DRUG THERAPY; COMPLICATION; FIBRINOLYTIC THERAPY; PROCEDURES; RISK FACTOR; THROMBOSIS;

ANTICOAGULANTS; ATRIAL FIBRILLATION; DRUG THERAPY, COMBINATION; FIBRINOLYTIC AGENTS; HUMANS; RISK FACTORS; THROMBOLYTIC THERAPY; THROMBOSIS;

EID: 84988815222     PISSN: 20556837     EISSN: 20556845     Source Type: Journal    
DOI: 10.1093/ehjcvp/pvv014     Document Type: Review

References (50)

1. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA 2001;285:2370-2375.
2. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ et al. Heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation 2014;129:e28-e292.
3. Lip GY, Laroche C, Dan GA, Santini M, Kalarus Z, Rasmussen LH et al. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) pilot general registry. Europace 2014;16:308-319.
4. Rohla M, Vennekate CK, Tentzeris I, Freynhofer MK, Farhan S, Egger F et al. Longterm mortality of patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation for acute and stable coronary artery disease. Int J Cardiol 2015;184C:108-114.
5. Kralev S, Schneider K, Lang S, Suselbeck T, Borggrefe M. Incidence and severity of coronary artery disease in patients with atrial fibrillation undergoing first-time coronary angiography. PLoS One 2011;6:e24964.
6. Almendro-Delia M, Valle-Caballero MJ, Garcia-Rubira JC, Munoz-Calero B, Garcia-Alcantara A, Reina-Toral A et al. Prognostic impact of atrial fibrillation in acute coronary syndromes: results from the ARIAM registry. Eur Heart J Acute Cardiovasc Care 2014;3:141-148.
7. Schmitt J, Duray G, Gersh BJ, Hohnloser SH. Atrial fibrillation in acute myocardial infarction: a systematic reviewof the incidence, clinical features and prognostic implications. Eur Heart J 2009;30:1038-1045.
8. LipGY, Windecker S, Huber K, Kirchhof P, Marin F, Ten Berg JM et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J 2014;35:3155-3179.
9. Lip GY, Karpha M. Anticoagulant and antiplatelet therapy use in patients with atrial fibrillation undergoing percutaneous coronary intervention: the need for consensus and a management guideline. Chest 2006;130:1823-1827.
10. Lopes RD, Elliott LE, White HD, Hochman JS, Van de Werf F, Ardissino D et al. Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial. Eur Heart J 2009;30:2019-2028.
11. Ruiz-Nodar JM, Marin F, Hurtado JA, Valencia J, Pinar E, Pineda J et al. Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis. J Am Coll Cardiol 2008;51:818-825.
12. LipGY, Huber K, Andreotti F, Arnesen H, Airaksinen KJ, Cuisset Tet al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/stenting. Thromb Haemost 2010;103:13-28.
13. FaxonDP, Eikelboom JW, Berger PB, HolmesDR, Bhatt DL, Moliterno DJ et al. Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. Thromb Haemost 2011;106: 572-584.
14. Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014;35:2541-2619.
15. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31:2369-2429.
16. Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006;367:1903-1912.
17. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146:857-867.
18. Connolly SJ, Pogue J, Hart RG, Hohnloser SH, Pfeffer M, Chrolavicius S et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation.NEngl J Med 2009;360: 2066-2078.
19. Sambola A, Ferreira-Gonzalez I, Angel J, Alfonso F, Maristany J, Rodriguez O et al. Therapeutic strategies after coronary stenting in chronically anticoagulated patients: the MUSICA study. Heart 2009;95:1483-1488.
20. Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE,Ho KK et al.Aclinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998;339:1665-1671.
21. Rubboli A, MilandriM, Castelvetri C, Cosmi B. Meta-analysis of trials comparing oral anticoagulation and aspirin versus dual antiplatelet therapy after coronary stenting. Clues for the management of patients with an indication for long-term anticoagulation undergoing coronary stenting. Cardiology 2005;104:101-106.
22. Karjalainen PP, Porela P, Ylitalo A, Vikman S, Nyman K, VaittinenMA et al. Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting. Eur Heart J 2007;28:726-732.
23. Dans AL, Connolly SJ,Wallentin L, Yang S,Nakamya J, BrueckmannMet al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation 2013;127: 634-640.
24. Sarno G, Lagerqvist B, Nilsson J, Frobert O, Hambraeus K, Varenhorst C et al. Stent thrombosis in new-generation drug-eluting stents in patients with STEMI undergoing primary PCI: a report from SCAAR. J Am Coll Cardiol 2014;64:16-24.
25. Stefanini GG, Siontis GC, CaoD, Heg D, Juni P, Windecker S. Short versus long duration of DAPT after DES implantation: a meta-analysis. J Am Coll Cardiol 2014;64: 953-954.
26. Lamberts M, Olesen JB, Ruwald MH, Hansen CM, Karasoy D, Kristensen SL et al. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. Circulation 2012;126:1185-1193.
27. Schulz-Schupke S, Byrne RA, Ten Berg JM, Neumann FJ, Han Y, Adriaenssens T et al. ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 versus 12 months of clopidogrel therapy after drug-eluting stenting. Eur Heart J 2015; doi:10.1093/eurheartj/ehu523.
28. Mauri L, Kereiakes DJ, YehRW, Driscoll-Shempp P, Cutlip DE, Steg PG et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.NEngl J Med 2014; 371:2155-2166.
29. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held Cet al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes.NEngl J Med 2009; 361:1045-1057.
30. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, RuzylloW, Gottlieb S et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes.NEngl J Med 2007;357:2001-2015.
31. Sarafoff N, Martischnig A,Wealer J, Mayer K, Mehilli J, Sibbing D et al. Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation. J Am Coll Cardiol 2013;61: 2060-2066.
32. Heidbuchel H, Verhamme P, Alings M, AntzM, HackeW, Oldgren J et al.EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J 2013;34:2094-2106.
33. Alexander JH, Lopes RD, Thomas L, Alings M, Atar D, Aylward P et al. Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 2014;35:224-232.
34. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361: 1139-1151.
35. Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med 2012;172:397-402.
36. Hohnloser SH, Oldgren J, Yang S,Wallentin L, Ezekowitz M, Reilly P et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation 2012;125:669-676.
37. GrahamDJ, Reichman ME,Wernecke M, Zhang R, Southworth MR,LevensonMet al. Cardiovascular, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated with Dabigatran orWarfarin for Non-Valvular Atrial Fibrillation. Circulation 2014.
38. Larsen TB, Rasmussen LH, Skjoth F, Due KM, Callreus T, RosenzweigMet al. Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol 2013;61: 2264-2273.
39. Larsen TB, Gorst-Rasmussen A, Rasmussen LH, Skjoth F, Rosenzweig M, Lip GY. Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation. Am J Med 2014;127:650-656 e5.
40. Larsen TB, Rasmussen LH, Gorst-Rasmussen A, Skjoth F, Rosenzweig M, Lane DA et al. Myocardial ischemic events in 'real world' patients with atrial fibrillation treated with dabigatran or warfarin. Am J Med 2014;127:329-336 e4.
41. Hansen ML, Sorensen R, Clausen MT, Fog-Petersen ML, Raunso J, Gadsboll N et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 2010;170:1433-1441.
42. Lamberts M, Gislason GH, Olesen JB, Kristensen SL, Schjerning Olsen AM, Mikkelsen A et al. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. J Am Coll Cardiol 2013;62: 981-989.
43. Dewilde WJ, Oirbans T, VerheugtFW, Kelder JC, De Smet BJ, Herrman JP et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 2013;381:1107-1115.
44. Oldgren J, Budaj A, Granger CB, Khder Y, Roberts J, Siegbahn A et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J 2011;32:2781-2789.
45. Alexander JH, Becker RC, Bhatt DL, Cools F, Crea F, Dellborg M et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation 2009;119:2877-2885.
46. Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011;365:699-708.
47. Mega JL, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 2009;374:29-38.
48. Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, BodeCet al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012;366:9-19.
49. Capodanno D, Lip GY, Windecker S, Huber K, Kirchhof P, Boriani G et al. Triple antithrombotic therapy in atrial fibrillation patients with acute coronary syndromes or undergoing percutaneous coronary intervention or transcatheter aortic valve replacement. EuroIntervention 2015;10:1015-1021.
50. Urban P, AbizaidA, Chevalier B, Greene S, Meredith I,MoriceMCet al. Rationale and design of the LEADERS FREE trial: A randomized double-blind comparison of the BioFreedom drug-coated stent vs the Gazelle bare metal stent in patients at high bleeding risk using a short (1 month) course of dual antiplatelet therapy. Am Heart J 2013;165:704-709.